<DOC>
	<DOC>NCT02105675</DOC>
	<brief_summary>The purpose of this study is to determine whether DCVAC/PCa added onto Standard of Care therapy can improve survival times for patients with Metastatic Castration Resistant Prostate Cancer</brief_summary>
	<brief_title>Phase II Study of DCVAC/PCa Added to Standard Chemotherapy for Men With Metastatic Castration Resistant Prostate Cancer</brief_title>
	<detailed_description />
	<mesh_term>Prostatic Neoplasms</mesh_term>
	<mesh_term>Docetaxel</mesh_term>
	<criteria>Men aged â‰¥ 18 years Histologically confirmed prostate cancer Presence of skeletal metastasis (by CT or PET or MRI) Disease progression documented by increasing PSA or two new lesions Eastern Cooperative Oncology Group (ECOG) Performance status 02 Confirmed brain and/or leptomeningeal metastases Prior chemotherapy for prostate cancer Peripheral neuropathy of Common Toxicity Criteria (CTC) grade 2 or greater Other uncontrolled intercurrent illness Treatment with immunotherapy against PCa Clinically significant cardiovascular disease Active autoimmune disease requiring treatment</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>Immunotherapy</keyword>
	<keyword>Metastatic</keyword>
	<keyword>Castrate Resistant</keyword>
	<keyword>Prostate Cancer</keyword>
	<keyword>Biological</keyword>
	<keyword>Vaccine</keyword>
</DOC>